Entering text into the input field will update the search result below

Esperion: Elucidating The Upcoming Clinical Binaries

Aug. 01, 2018 5:13 AM ETEsperion Therapeutics, Inc. (ESPR)14 Comments


  • Esperion is innovating two promising novel medicines to potentially cut into the vast hyperlipidemia market.
  • Bempedoic acid is a first-in-class “prodrug” that demonstrated the strong LDL-cholesterol reduction. Combination of bempedoic acid and ezetimibe delivered even more robust clinical outcomes.
  • Two upcoming clinical binaries can catapult the shares to a higher level.
  • Members of my private investing community, Integrated BioSci Investing, can follow this idea, as well as my other top picks with access to my model portfolio. Start your free trial today >>

Esperion (NASDAQ:ESPR) is an interesting bioscience that piqued our interest due to the strong insider purchases. A member of Integrated BioSci Investing (“IBI”) also requested us to conduct a research on this firm. That said, we’ll share with readers the fruits of our research, which represent our efforts to assist IBI members in their own due diligence. As follows, Esperion is a growth company, powered by two highly promising oral molecules: bempedoic acid and bempedoic acid in combination with ezetimibe potentially used to manage high cholesterol (hypercholesterolemia). There are multiple ongoing developments that can improve the investing prospects. In this research, we’ll present a fundamental analysis while focusing on the upcoming clinical binaries.

Figure 1: Esperion stock chart. (Source: StockCharts)

Fundamental Analysis

Based in Ann Arbor, Michigan, Esperion is focused on the innovation and commercialization of novel therapeutics to service the hyperlipidemia market. The company is developing two stellar molecules - oral pills of bempedoic acid and bempedoic acid with ezetimibe combination - potentially used to manage high LDL-cholesterol (LDL-cholesterol) associated with hyperlipidemia. Moreover, they seek to lower the heart disease (cardiovascular) risks associated with high blood cholesterol (Figure 2).

Figure 2: Therapeutic pipeline. (Source: Esperion)

Designed as a convenient once-daily, oral LDL-cholesterol lowering drug, bempedoic acid is potentially indicated for patients suffering from a specific form of hyperlipidemia (i.e., hypercholesterolemia or high LDL-cholesterol). As a first-in-class, bempedoic acid is a “pro-drug” that is converted into a coenzyme A (COA) derivative (i.e., ETC-1002-CoA) when entering circulation. ETC-1002-CoA then blocks a key enzyme - ATP citrate lyase (ACL) - that, in and of itself, provides the substrate for the cholesterol and fatty acid synthesis in the liver. Blocking ACL results in less cholesterol production in the midst of an upregulation of LDL receptor in the liver (Figure 3). Altogether, the end results are the lowering of LDL-cholesterol and reducing cardiovascular risks.

Author’s Notes: We’re honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (“IBI”) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, Madrigal and Kite procured over 179%, 177%, 168%, 212%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, which we published in advance and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

This article was written by

The #1 Biotech Service for Growth Investing and Catalyst Power Trading

As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading. 

Since inception, our flagship portfolio has delivered over 
31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.

Check out some of
our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.

In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis.
The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.

Follow us for the latest research. And,
take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!

Check out Dr. Harvey’s
LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Our research articles are best used as starting points in your own due diligence. We are not registered investment advisors and our articles are not construed as professional investment advice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.